SCYNEXIS Free Cash Flow Per Share 2013-2024 | SCYX

SCYNEXIS free cash flow per share from 2013 to 2024. Free cash flow per share can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis

SCYNEXIS Free Cash Flow Per Share 2013-2024 | SCYX

SCYNEXIS free cash flow per share from 2013 to 2024. Free cash flow per share can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$73.4B
Chugai Pharmaceutical (CHGCY)$72.5B
Takeda Pharmaceutical (TAK)$42.2B
Merck (MKKGY)$18.5B
Sandoz Group AG (SDZNY)$17.9B
Astellas Pharma (ALPMY)$17.4B
United Therapeutics (UTHR)$16.1B
Neurocrine Biosciences (NBIX)$14B
Summit Therapeutics (SMMT)$13.5B
Shionogi (SGIOY)$11.9B
Madrigal Pharmaceuticals (MDGL)$6.8B
Orion OYJ (ORINY)$6.2B
Ionis Pharmaceuticals (IONS)$5.5B
Corcept Therapeutics (CORT)$5.2B
Crinetics Pharmaceuticals (CRNX)$4.8B
PTC Therapeutics (PTCT)$3.5B
Recursion Pharmaceuticals (RXRX)$2.8B
Dyne Therapeutics (DYN)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.6B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.4B
NewAmsterdam Pharma (NAMS)$2.4B
Centessa Pharmaceuticals (CNTA)$2.3B
Soleno Therapeutics (SLNO)$2B
Indivior (INDV)$1.7B
Xencor (XNCR)$1.7B
BioCryst Pharmaceuticals (BCRX)$1.6B
Evotec AG (EVO)$1.5B
Ocular Therapeutix (OCUL)$1.4B
Harrow (HROW)$1.3B
Guardian Pharmacy Services (GRDN)$1.3B